SUBSCRIBE
SUBSCRIBE

Inozyme Pharma

IN THE PRESS
Inozyme Pharma was acquired by BioMarin Pharmaceuticals in July 2025.
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
May 16, 2025
 · 
18 min read
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 15, 2025
 · 
18 min read
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
April 11, 2025
 · 
5 min read
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
 · 
1 min read
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
March 10, 2025
 · 
10 min read
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
 · 
1 min read
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
February 21, 2025
 · 
3 min read
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
January 10, 2025
 · 
12 min read
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 28, 2024
 · 
1 min read
Inozyme Pharma to Present at Upcoming Investor Conferences
November 11, 2024
 · 
2 min read
NEWS
Drug Development
Clinical Catch-Up: January 4-8
The new year began with a fairly low level of clinical trial news. Here’s a look.
January 8, 2021
 · 
5 min read
 · 
Mark Terry
Business
BioSpace Movers & Shakers, November 13
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
November 12, 2020
 · 
7 min read
 · 
Alex Keown
Business
BioSpace Movers & Shakers, Oct. 16
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
October 15, 2020
 · 
7 min read
 · 
Alex Keown
Investor
Genetown
Cambridge Startup Inozyme Nabs $49M and a Roster Packed With Seasoned Vets
The $49M in Series A funding will be used to develop the company’s enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the clinic.
November 15, 2017
 · 
2 min read
 · 
Alex Keown
Load More